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a b s t r a c t
Atrial natriuretic peptide (ANP) is a cardiovascular biomarker that might be useful in assessing the sever-
ity of cardiac disease in horses. Plasma ANP concentrations (CpANP) were compared between horses with
heart disease but normal chamber size and function (Group A; n = 6), horses with heart disease associated
with left atrial (LA) enlargement, LA dysfunction, and/or left ventricular (LV) enlargement (Group B;
n = 5), and horses with no clinically apparent cardiovascular disease (Group C; n = 13).
The median (min–max) for CpANP was signiﬁcantly higher in Group B (53.5 (36.0–70.7) pg/mL), com-
pared to Group A (12.5 (6.3–19.8) pg/mL) and Group C (13.4 (7.2–34.0) pg/mL). Backwards stepwise mul-
tiple linear regression showed that CpANP in horses with heart disease was related to LA dimensions, but
not to LV size, LA function, and LV function. The results indicated that CpANP in horses might be useful in
detecting LA enlargement and that CpANP could be related to the severity of cardiac disease. Larger pro-
spective studies are necessary to conﬁrm these results.
 2011 Elsevier Ltd. All rights reserved.
Introduction
Natriuretic peptides are widely used as cardiac biomarkers in
human and veterinary medicine (van Kimmenade and Januzzi,
2009). Physiologically, they counteract the effects of the renin–
angiotensin–aldosterone system and regulate ﬂuid balance and
blood pressure by a variety of renal, vascular, and cardiac mecha-
nisms (McGrath et al., 2005). Natriuretic peptides are produced
by atrial and ventricular myocytes and released into the blood in
response to a variety of triggers.
The plasma concentration of brain (B-type) natriuretic peptide
(BNP; a peptide more abundant in ventricular myocytes) and ami-
no-terminal proBNP (NT-proBNP; the more stable, inactive rem-
nant that is released when BNP is activated from its prohormone
proBNP) are most widely used in human medicine, particularly
to diagnose diseases associated with ventricular dysfunction and
heart failure (Daniels and Maisel, 2007). However, measurement
of plasma BNP and NT-proBNP concentrations requires species-
speciﬁc assays, since the amino acid sequence of BNP varies among
species (Liu et al., 2002). To date, an assay to measure equine BNP
or NT-proBNP concentrations is not commercially available.
Conversely, the amino acid sequence of atrial natriuretic pep-
tide (ANP) is highly conserved among species, allowing the use of
commercially available human assays to measure plasma ANP con-
centrations (CpANP) in horses (Richter et al., 1998). ANP is primarily
produced by atrial myocytes, although its expression can also be
enhanced in diseased ventricular myocytes from experimental ani-
mals and in human patients (Ruskoaho, 2003). In addition to atrial
stretch or increased pacing frequency, ANP expression and secre-
tion can be increased by a variety of stimuli, including endothe-
lin-1, arginine vasopressin, angiotensin II, a-adrenergic agonists,
thyroid hormones, glucocorticoids, growth hormone, prostaglan-
dins, vitamin D, thrombin (de Bold et al., 1996; Ruskoaho, 2003)
and hypoxia (Chen, 2005). The increased ANP secretion following
atrial myocardial stretch due to volume or pressure overload is cer-
tainly of particular interest in equine cardiology, since horses fre-
quently suffer from mitral regurgitation (MR) or atrial ﬁbrillation
(AF), which both affect atrial size and mechanical function.
Storage of ANP in the equine atrial myocytes and its release dur-
ing stretching of atrial tissue (as occurring during exercise) has
been documented in healthy horses (Mifune et al., 1991; Kokkonen
et al., 1995). More recently, it has been shown that CpANP may be
slightly elevated in horses with valvular regurgitation associated
with left atrial (LA) enlargement or combined LA and left ventricu-
lar (LV) dilation, compared to healthy horses (Gehlen et al., 2007).
However, the use of ANP as a cardiac biomarker has not yet been
1090-0233/$ - see front matter  2011 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tvjl.2011.06.035
⇑ Corresponding author. Tel.: +41 44 635 83 57.
E-mail address: dtrachsel@vetclinics.uzh.ch (D.S. Trachsel).
The Veterinary Journal 192 (2012) 166–170
Contents lists available at ScienceDirect
The Veterinary Journal
journal homepage: www.elsevier .com/ locate / tv j l
Author's personal copy
fully investigated in horses. It is unknown to what extent CpANP in-
creases with various heart diseases and whether the measurement
of CpANP is of any diagnostic or prognostic value in horses.
The aim of this study was to measure CpANP in a group of horses
suffering from various heart diseases and to investigate the associ-
ation between CpANP and echocardiographic measurements of
chamber dimensions and chamber function. We hypothesised that
horses with cardiac disease associated with LA enlargement, LA
dysfunction, and/or LV enlargement would have increased CpANP
compared to horses with cardiac disease and normal LA and LV size
and function and to horses without clinically apparent heart
disease.
Material and methods
Study population
The main study population consisted of 11 horses that were presented to the
Equine Hospital of the Vetsuisse Faculty of the University of Zurich for cardiovascu-
lar examination because of existing heart disease (Groups A and B). The population
consisted of one female, seven castrated males, and three intact males of various
breeds (six Warmbloods, two Arabians, one Thoroughbred, one Friesian, one Paso
Fino) with a median age of 14 years (range 3–29 years) and a bodyweight (BW)
of 530 kg (range 360–600 kg).
Another group of 13 horses served as control group (Group C). This group had
no history and no clinical signs of heart disease, no audible heart murmurs, and
no cardiac arrhythmias and was therefore considered free of cardiac disease. No
echocardiographic examinations were performed in this group. This group com-
prised six females, six castrated males, and one intact male of various breeds (six
Warmbloods, two Icelandic horses, one Appaloosa, one Palomino, one Zangersheide,
one Shire, one Freiberger) with a median age of 8 years (range 3–19 years) and a
median BW of 510 kg (range 400–690 kg; n = 8).
All examinations, including physical examination, and collection of blood sam-
ples, were performed within the routine patient workup and therefore did not re-
quire approval by the district veterinary ofﬁce. Owners’ consent was obtained.
Echocardiographic examination
All horses of group A and B underwent a thorough cardiologic examination,
including physical examination, thoracic and cardiac auscultation, electrocardiog-
raphy, and standardised transthoracic two-dimensional (2DE) and M-mode echo-
cardiography (Boon, 1998; Bonagura et al., 2010). Echocardiographic recordings
(GE Vivid 7 Dimension (BTO6) with a M4S Phased Array Transducer, GE Health-
care) were obtained by three trained and experienced clinicians within the routine
workup of the cases. All measurements were performed ofﬂine from the digitally
stored cine loop recordings by one single operator (DST) for the purpose of this
study.
The echocardiographic examination included conventional 2DE and M-mode
measurements of LV dimensions and LV systolic function (Boon, 1998; Bonagura
et al., 2010) as well as 2DE measurements of LA dimensions and LA mechanical
function using previously described imaging standards (Schwarzwald et al.,
2007). Three cardiac cycles were measured and averaged for further analyses.
As the study population showed a wide range of BW, the measurements were cor-
rected for differences in weight according to the principles of allometric scaling
(Brown et al., 2003; Cornell et al., 2004). Speciﬁcally, the measurements of cham-
ber dimensions were normalised to a BW of 500 kg [500] using the following
equations:
Chamber diameter ½500 ¼ Measured chamber diameter=BW1=3  5001=3
Chamber area ½500 ¼ Measured chamber area=BW2=3  5002=3
Linear echocardiographic indices of LA and LV size included maximum LA
diameter measured in a right parasternal long-axis 2DE recording at end-systole
(LADmax); LADmax normalised to a BW of 500 kg (LADmax [500]); left ventricular
internal diameter at end-diastole (LVIDd) and peak systole (LVIDs) measured in a
right parasternal short-axis M-mode recording at the level of the chordae tendi-
neae; and LVIDd normalised to a BW of 500 kg (LVIDd [500]).
Uni-dimensional (linear) indices of LA function are not considered reliable
(Schwarzwald et al., 2007) and therefore were not calculated in this study. The
LV fractional shortening (LV FS) was calculated as a uni-dimensional index of LV
function based on M-mode measurements of the LVID (LV FS = (LVIDd  LVIDs)/
LVIDd  100).
Two-dimensional (area-based) indices of LA and LV size included maximum LA
area measured in a right parasternal long-axis 2DE recording at end-systole
(LAAmax); LAAmax normalised to a BW of 500 kg (LAAmax [500]); LA area prior to
active contraction measured in a right parasternal long-axis 2DE recording at the
onset of the electrocardiographic P wave (LAAa); minimum LA area measured in a
right parasternal long-axis 2DE recording at the time of mitral valve closure (LAA-
min); maximum LA area measured in a right parasternal short-axis 2DE recording at
end-systole (LAsxAmax); LAsxAmax normalised to a BW of 500 kg (LAsxAmax [500]); LV
internal area measured in a right parasternal long-axis 2DE recording at end-dias-
tole (LVIAd) and at peak systole (LVIAs); and LVIAd normalised to a BW of 500 kg
(LVIAd [500]).
Two-dimensional (area-based) indices of LA and LV function included active
fractional area change of the LA (Active LA FAC = (LAAa  LAAmin)/LAAa  100); pas-
sive fractional area change of the LA (Passive LA FAC = (LAAmax  LAAa)/
LAAmax  100); active-to-total LA area change (active:total LA AC = (LAAa  LAAmin)/
(LAAmax  LAAmin)); and fractional area change of the LV based on long-axis 2DE
measurements of LVIA (LV FAC = (LVIAd  LVIAs)/LVIAd  100).
Grading of valvular regurgitations was based on a subjective grading scale (1–9)
considering the high-velocity jet area, the regurgitant signal duration, and the num-
ber of imaging planes in which the high-velocity jet could be observed in the receiv-
ing chamber (Young et al., 2008). The diagnosis of LA and LV enlargement and/or
dysfunction was based on the consensus of two independent observers (DST,
CCS). In addition to subjective assessment, quantitative indices of LA and LV size
and function were measured or calculated as described above and (where available
for the respective breed and body size) compared to reference ranges published in
the literature (Boon, 1998; Schwarzwald et al., 2007; Bonagura et al., 2010) and/or
established in our echocardiography laboratory. During echocardiographic record-
ings, ofﬂine analyses, and ﬁnal assessment, the observers were blinded to the re-
sults of the CpANP measurements.
Signalment, diagnoses, and echocardiographic indices of all horses are listed in
Table 1. Six horses had normal LA and LV dimensions and mechanical function by
echocardiography (Group A). One of the horses had MR, two had aortic regurgita-
tion (AR), one had AR and a restrictive ventricular septal defect (VSD), one showed
both AR and MR, and one showed MR, AR, and traces of tricuspid regurgitation (TR)
and pulmonic regurgitation (PR). Five horses suffered from cardiac disease associ-
ated with LA enlargement, LA dysfunction, and/or LV enlargement (Group B). In this
group, one horse had LA dysfunction associated with chronic AF (lasting at least
1 year) without concomitant valvular diseases and without LA and LV enlargement,
one horse had moderate to severe AR and trivial to mild MR with an enlarged LV but
normal LA size and function, and three horses had increased LV dimensions con-
comitant to LA enlargement and/or LA dysfunction, associated with multiple valvu-
lar regurgitations, AF, and aorto-cardiac ﬁstula, respectively. Two horses in Group B
showed signs of congestive heart failure (CHF).
Blood sampling
The very short half-life time (estimated to be approximately 2–5 min in sheep
and humans (Biollaz et al., 1987; Mukaddam-Daher et al., 1994) warranted careful
and immediate sample processing. Hence, blood samples were taken by jugular
venepuncture and placed into prepared blood tubes containing potassium-EDTA
(1.6 mg EDTA/mL blood, Sarstedt) and aprotinine (lyophilised aprotinine
(600 KIU/mL blood), Sigma–Aldrich). They were then immediately cooled on ice
and centrifuged for 5 min at 1570 g and 4 C. Plasma was then harvested, trans-
ferred into cryovials (TTP Techno Plastic Products), and frozen at 80 C within
15 min after sampling.
Laboratory analysis
Human ANP has previously been shown to be stable at 80 C for at least
12 months (Zolty et al., 2008). All samples were therefore analysed within
12 months after collection. The ANP was extracted and measured using a commer-
cially available radioimmunoassay (RIA) kit (RIA kit RK-005-06: ANPa (1–28), Phoe-
nix Pharmaceuticals) and a gamma-counter (GAMMAmatic I, Kontron Analytical,
W +W Electronic AG), following the manufacturer’s instructions. The target se-
quence recognised by the assay has previously been shown to be 100% homologous
in horses and humans (Richter et al., 1998).
Data analyses and statistics
Data analyses and statistics were performed using commercial computer soft-
ware (GraphPad Prism, version 5.03, GraphPad Software, SigmaStat, version 3.5, Sy-
stat Software). Because of the low sample size within the groups, no normality tests
were performed and non-parametric statistics were chosen. Continuous variables
were summarised using medians and ranges. The CpANP of the three Groups were
compared using a Kruskal–Wallis one-way analysis of variance with Dunn’s post
hoc test for multiple comparisons. Backwards stepwise multiple linear regression
analyses were performed including all horses in Groups A and B to assess the rela-
tionship between CpANP and weight-corrected echocardiographic indices of LA and
LV size and function. Linear measurements and area measurements were analysed
separately. Measurements of LA and LV dimensions were forced into the equation,
whereas the indices of LA and LV systolic function were allowed to be eliminated by
the backwards stepwise regression model. The level of signiﬁcance was set at
P < 0.05.
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Results
The CpANP expressed as median (min–max) in Group A, B and C
were 12.5 (6.3–19.8), 53.5 (36.0–70.7), and 13.4 (7.2–34.0) pg/mL,
respectively (Fig. 1, Table 1). The CpANP in Group B was signiﬁcantly
higher compared to Groups A and C, respectively (P < 0.05). There
was no statistically signiﬁcant difference in CpANP between Group
A and Group C.
The multiple regression analysis showed that CpANP could be
predicted from LADmax [500] (P = 0.033), whereas the LVIDd [500]
(P = 0.743) and LV FS (P = 0.056) did not signiﬁcantly add to the
ability of equation to predict CpANP. Similarly, the CpANP could be
predicted from LAAmax [500] (P = 0.003), whereas the effect of
LVIAd [500] (P = 0.074) was not signiﬁcant. Active LA FAC and LV
FAC did not signiﬁcantly add to the ability of the equation to pre-
dict CpANP and were removed from the model during the stepwise
procedure. The power of the performed tests was 0.961 for linear
indices and 0.987 for area indices. The relations of LADmax [500]
and LAAmax [500], respectively, to CpANP are shown in Fig. 2.
Discussion
The results of this study indicated that CpANP was increased in
horses with cardiac disease associated with cardiac chamber
enlargement and/or dysfunction and that CpANP was directly re-
lated to the degree of LA enlargement.
The study population consisted of a group of horses with car-
diac disease and normal LA and LV dimensions and mechanical
function by echocardiography (Group A) and a group of horses
with cardiac disease associated with LA enlargement, LA dysfunc-
tion, and/or LV enlargement (Group B). In Group A, the CpANP
was slightly lower than values reported by Gehlen et al. (2007)
in Warmblood horses with valvular regurgitation and normal
chamber dimensions (20.1 ± 5.6 pg/mL, mean ± SD). In the latter
study, CpANP in this group was not signiﬁcantly different from
CpANP in healthy Warmblood horses (21.0 ± 5.4 pg/mL) (Gehlen
et al., 2007). Similarly, in our study there was no difference in
CpANP between Group A and Group C (control group). Furthermore,
CpANP in our control group was similar to the concentrations re-
ported by Gehlen et al. (2007) in healthy Warmblood horses and
similar to those reported in healthy Finnhorse trotters (18 ±
1 pg/mL, mean ± SE) and healthy Standardbreds (15 ± 2 pg/mL,
mean ± SE) (Kokkonen et al., 1995). It could therefore be inferred
that horses with cardiac disease and normal chamber dimensions
could not reliably be differentiated from healthy horses by use of
CpANP.
Conversely, CpANP may be suitable to identify left-sided cham-
ber enlargement or dysfunction in horses with cardiac disease,
since the CpANP in Group B was signiﬁcantly higher compared
to Group A, with no overlap between groups seen in this study.
Notably, CpANP in Group B was markedly higher than the CpANP
reported by Gehlen et al. (2007) in horses with enlarged LA
but normal LV dimensions (22.9 ± 11.0 pg/mL), and in horses
with both LA and LV enlargement (27.6 ± 17.4 pg/mL), neither
of which was signiﬁcantly different from healthy Warmblood
horses (21.0 ± 5.4 pg/mL) in the aforementioned study.
The linear regression model revealed that CpANP in horses with
cardiac disease was signiﬁcantly related to LA dimensions, but not
to LV dimensions or indices of LA and LV systolic function. The ab-
sence of a signiﬁcant inﬂuence of LV dimensions in our study pop-
ulation was interesting, as enhanced ANP expression has been
demonstrated in ventricular disease in experimental models and
in human patients (Ruskoaho, 2003). However, this study only in-
cluded a small number of horses and might not have allowed iden-
tifying all inﬂuencing factors. Furthermore, the inﬂuence of LA
Fig. 1. Plasma atrial natriuretic peptide (ANP) concentrations (CpANP). Group A:
Horses with heart disease but normal left atrial (LA) and left ventricular (LV) size
and mechanical function. Group B: Horses with heart disease associated with LA
enlargement, LA dysfunction, and/or LV enlargement; , horse with LA dysfunction
because of lone atrial ﬁbrillation (AF) but normal LA and LV dimensions; j, horse
with LV enlargement but normal LA size and mechanical function. Group C: Horses
without history or clinical sings of heart disease. The horizontal lines represent the
median CpANP in each group. P < 0.05; n.s., not signiﬁcant.
Fig. 2. Plasma ANP concentration (CpANP) in relation to LA diameter and LA area,
respectively. LADmax [500], Maximum LA diameter measured in a right parasternal
long-axis view recording at end-systole normalised to a BW of 500 kg. LAAmax [500],
Maximum LA area measured in a right parasternal long-axis view recording at end-
systole, normalised to a BW of 500 kg.
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dysfunction could not be assessed thoroughly as there was only
one horse with LA dysfunction because of lone AF. Therefore, larger
studies including horses with a wide spectrum of disease severity
will be necessary to conﬁrm these ﬁndings and to conclusively
determine the relative inﬂuence of LA and LV enlargement and
mechanical dysfunction as well as right heart enlargement and
dysfunction on CpANP.
In the current study, the relation of CpANP to the two-dimen-
sional area measurements seemed to be slightly stronger than
the relation to the linear measurements. This might be explained
by the fact that area measurements better represent LA dimen-
sions, compared to linear measurements (Lang et al., 2006;
Schwarzwald et al., 2007). This supported our contention that area
measurements should be preferred or at least used in addition to
linear measurements for echocardiographic quantiﬁcation of
chamber dimensions and chamber function in studies on cardiac
biomarkers.
The absence of a well deﬁned control group consisting of
healthy horses without cardiac disease, as conﬁrmed by echocardi-
ography, was one of the limitations of this study. Furthermore,
only a relatively small number of horses with a variety of cardiac
disorders were enrolled. Therefore, the results did not permit a
comprehensive assessment of the diagnostic value of CpANP in spe-
ciﬁc cardiac diseases, nor did they clearly differentiate the effects
of atrial vs. ventricular enlargement on CpANP.
Conclusions
The results of this study indicated that measurement of CpANP in
horses provides potentially useful data on cardiac chamber dimen-
sions and that CpANP might be related to the severity of disease in
horses with cardiac disorders. Larger prospective clinical studies
are required to determine the diagnostic and prognostic value of
ANP in horses with cardiac disease.
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